类风湿性关节炎和支气管喘与单细胞和巨细胞中PLAUR基因表达的变化有关
Petra Kulíšková1, Ondřej Zapletal1, Peter Slanina2
1Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic; Department of Clinical Immunology and Allergology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Gene
|October 16, 2025
概括
改变的泌尿酸酶等离子素激活体受体 (uPAR) 基因表达和单细胞和巨细胞中的拼接与类风湿性关节炎 (RA) 和支气管喘 (BA) 有关. 特定的UPAR异型可能表明疾病进展.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 血原激活系统与类风湿性关节炎 (RA) 和支气管喘 (BA) 的病原发生有关.
- 在RA和BA中观察到尿激酶等离子体激活剂受体 (uPAR) 水平升高.
- 通过替代拼接,PLAUR基因产生膜结合 (muPAR) 和可溶性 (suPAR) 异型.
研究的目的:
- 调查改变的PLAUR表达和RA和BA中的替代拼接的作用.
- 确定PLAUR表达变化是否有助于疾病易感性和进展.
主要方法:
- 使用定量RT-PCR分析了PLAUR转录水平和拼接模式.
- 从健康志愿者,RA患者和BA患者中分离出单细胞和M0/M1巨细胞.
- 分析根据疾病严重程度进行了分层.
主要成果:
- 在RA和BA患者的单细胞和M0巨细胞中,PLAUR的表达显著升高.
- 温和的BA显示了整体PLAUR表达的增加.
- 严重的BA表现出缺少异构6的suPAR和缺少异构5的muPAR异构的丰富.
结论:
- 增加PLAUR表达和替代拼接事件有助于RA和BA免疫病理学.
- suPAR异型的丰富性可能成为疾病进展的潜在生物标志物.
- 需要进一步的功能研究来确认临床相关性.
相关概念视频
Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K
Asthma-I: Introduction
3.4K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.4K
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Genome-wide Association Studies-GWAS
15.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.3K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K


